Tagrisso 80 mg is an oral prescription medicine containing 80 mg of osimertinib per tablet. Osimertinib belongs to a class of targeted anticancer medicines called EGFR tyrosine kinase inhibitors. It inhibits specific mutated forms of the epidermal growth factor receptor involved in the growth and survival of certain lung cancer cells.
The medicine is used only for defined clinical indications and requires appropriate medical supervision.
The generic name is osimertinib. Tagrisso is the brand name associated with this active ingredient.
The brand name identifies the marketed product, while the generic name identifies the active medicine. Patients should check both the product name and active ingredient on their packaging to ensure that the medicine matches their prescription.
Tagrisso is used in selected patients with EGFR-mutated non-small cell lung cancer (NSCLC). Depending on the applicable product authorization, treatment settings may include adjuvant treatment after complete surgical removal of a tumor, treatment following certain chemoradiation regimens, and treatment of locally advanced or metastatic disease.
In selected cases, it may also be prescribed with pemetrexed and platinum-based chemotherapy. Eligibility depends on the specific indication, molecular test results, disease stage and previous treatment.
The principal disease area is non-small cell lung cancer with particular EGFR mutations. NSCLC is a group of lung cancers that includes several distinct cancer types.
Tagrisso is not suitable for every NSCLC diagnosis. Molecular testing is important because the medicine targets specific altered forms of EGFR. The treating oncologist determines whether the test results and clinical circumstances support its use.
Osimertinib inhibits certain mutated forms of EGFR, a receptor involved in cell signaling. Some EGFR mutations cause abnormal growth signals that support cancer-cell survival and proliferation.
By blocking susceptible mutant EGFR activity, osimertinib interferes with these signals. It also has activity against the T790M resistance mutation, which can contribute to resistance to certain earlier EGFR-targeted medicines.
Its targeted action does not guarantee a response, and resistance may develop during treatment.
The product featured on this website is Tagrisso 80 mg, an oral tablet containing 80 mg of osimertinib.
Other strengths or presentations may be available in some markets. Availability and authorization vary by country, so patients should confirm the strength stated on their actual packaging and follow their prescription.
The tablet strength alone does not establish the correct regimen for every patient.
AstraZeneca is associated with the reference Tagrisso brand. However, the manufacturer, marketing authorization holder, importer and distributor for a particular product presentation may differ according to the country and supply arrangement.
Patients should review the company information printed on their packaging and consult a pharmacist if they need help identifying the organization responsible for their specific product.
The usual adult regimen described in official prescribing information is 80 mg taken orally once daily. The prescribed regimen may be modified by a clinician if adverse reactions or other clinical circumstances require it.
Patients should follow their own prescription and the current patient leaflet. They should not independently increase, reduce, interrupt or discontinue treatment.
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Patients should follow the food and administration instructions in the current official patient leaflet for their product. They should not assume that the instructions for another medicine apply to osimertinib.
If there is uncertainty about food, swallowing or the timing of a dose, a pharmacist or oncology professional can clarify the applicable instructions.
Possible side effects include diarrhea, rash, dry skin, nail inflammation and mouth inflammation. Fatigue or reduced appetite may also occur in some patients.
The severity of side effects varies. Patients should report persistent diarrhea, worsening skin reactions, mouth problems that interfere with eating or drinking, or other symptoms that affect daily activities.
A healthcare professional can assess the symptoms and recommend appropriate management.
Yes. Important serious risks include interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
New or worsening breathing difficulties, fainting, a rapid or irregular heartbeat, chest symptoms, significant eye pain or visual changes require prompt medical assessment. Severe or rapidly worsening symptoms may require emergency care.
Patients should follow the monitoring plan provided by their oncology team and report concerning symptoms without delay.
Potential interactions and overlapping safety risks must be assessed for each patient's medication regimen. Some medicines can affect heart rhythm, while other combinations may require additional precautions or monitoring.
Patients should tell their healthcare team about all prescription medicines, nonprescription products, vitamins, supplements and herbal remedies they use. They should not start a new medicine or supplement without checking whether it is appropriate during treatment.
Patients should follow the missed-dose instructions in the official patient leaflet. They should not take an extra or double dose to compensate for a missed tablet.
If the correct next step is unclear, the patient should contact their pharmacist or oncology team. Repeated missed doses should also be discussed with the healthcare team so that practical difficulties can be addressed safely.
Tagrisso should be stored according to the instructions on the packaging and official patient leaflet. Patients should check the expiry date and keep the medicine out of the reach of children.
The product should not be used if it is expired or if its identity and condition are uncertain. A pharmacist can advise on appropriate storage and disposal under local requirements.
Pregnancy requires specific medical consideration because osimertinib may cause fetal harm. Patients who are pregnant, planning pregnancy or who think they may be pregnant should contact their oncology team promptly.
The treating clinician should explain the applicable precautions and contraception requirements based on the current prescribing information. Patients should not make independent treatment decisions or delay seeking advice.
Breastfeeding requires discussion with the treating healthcare professional because the medicine may pose risks to a nursing infant. The appropriate precautions and any recommended restrictions should be based on current official prescribing information and the patient's clinical circumstances.
Patients should discuss breastfeeding before starting treatment and before making any changes to their treatment or feeding plans.
Patients should tell their healthcare professional about their complete medical history, including relevant heart, lung and eye conditions, previous serious medicine reactions and all medicines or supplements they use.
They should also discuss pregnancy, contraception and breastfeeding where applicable. Molecular test results and previous cancer treatments are important because they help determine whether the medicine is appropriate for the intended indication.
Patients should promptly report new or worsening breathing difficulties, persistent cough, severe diarrhea, significant skin reactions or other concerning symptoms.
Potentially serious symptoms include fainting, chest pain, a rapid or irregular heartbeat, severe shortness of breath, significant eye pain or sudden changes in vision. These symptoms require urgent medical assessment, and severe symptoms may require emergency assistance.
Patients should not wait for a routine appointment or a website response when urgent medical care is needed.
Patients can review the brand name, active ingredient, strength, manufacturer information, batch or lot number, expiry date and packaging condition. The details should be consistent with the prescription and applicable official product documentation.
These checks can identify discrepancies but cannot independently prove authenticity. A brand name or package photograph is not sufficient evidence that a product is genuine.
Patients should obtain prescription medicines through legitimate supply channels and ask a pharmacist or appropriate authority to assess products of uncertain origin.
No treatment outcome can be guaranteed. Depending on the indication, Tagrisso may reduce the risk of recurrence or help control cancer in eligible patients. The benefits and treatment objectives differ between adjuvant, post-chemoradiation and advanced-disease settings.
The medicine does not guarantee a cure, and outcomes vary. The treating oncology team can explain the goals of treatment and assess the response over time.